Gladstone Institute of Neurological Disease and Taube-Koret Center for Huntington's Disease Research and Consortium for Fronto-temporal Dementia Research, University of California, San Francisco, CA 94158, USA.
Proc Natl Acad Sci U S A. 2010 Sep 28;107(39):16982-7. doi: 10.1073/pnas.1004498107. Epub 2010 Sep 10.
Autophagy is an intracellular turnover pathway. It has special relevance for neurodegenerative proteinopathies, such as Alzheimer disease, Parkinson disease, and Huntington disease (HD), which are characterized by the accumulation of misfolded proteins. Although induction of autophagy enhances clearance of misfolded protein and has therefore been suggested as a therapy for proteinopathies, neurons appear to be less responsive to classic autophagy inducers than nonneuronal cells. Searching for improved inducers of neuronal autophagy, we discovered an N(10)-substituted phenoxazine that, at proper doses, potently and safely up-regulated autophagy in neurons in an Akt- and mTOR-independent fashion. In a neuron model of HD, this compound was neuroprotective and decreased the accumulation of diffuse and aggregated misfolded protein. A structure/activity analysis with structurally similar compounds approved by the US Food and Drug Administration revealed a defined pharmacophore for inducing neuronal autophagy. This pharmacophore should prove useful in studying autophagy in neurons and in developing therapies for neurodegenerative proteinopathies.
自噬是一种细胞内的物质周转途径。它与神经退行性蛋白病(如阿尔茨海默病、帕金森病和亨廷顿病)有特殊的相关性,这些疾病的特征是错误折叠的蛋白质积累。虽然自噬的诱导增强了错误折叠蛋白的清除,因此被认为是治疗蛋白病的一种方法,但与非神经元细胞相比,神经元对经典自噬诱导剂的反应似乎较差。为了寻找更好的神经元自噬诱导剂,我们发现了一种 N(10)-取代的吩嗪,在适当的剂量下,它能够以 Akt 和 mTOR 非依赖性的方式强有力且安全地上调神经元中的自噬。在亨廷顿病的神经元模型中,该化合物具有神经保护作用,并减少了弥漫性和聚集性错误折叠蛋白的积累。与美国食品和药物管理局批准的结构相似的化合物进行的结构/活性分析揭示了诱导神经元自噬的明确药效团。这个药效团应该有助于研究神经元中的自噬,并开发治疗神经退行性蛋白病的方法。